Tag: pharmaceutical companies
-
Does Core One Labs (COOL.C) have a solution for psilocybin’s dosing problem?
Core One’s objective in developing the psilocybin thinstrips is to assist with the delivery of revolutionary psychedelic treatment methods to address mental health conditions such as depression, anxiety and addictions.
-
Core One Labs (COOL.C) acquires 100% of a synthetic psilocybin company
“This transaction will significantly enhance Core One Labs’ ability to innovate our psychedelic drug development program,” stated Joel Shacker, CEO of Core Labs.
-
Algernon Pharmaceuticals (AGN.C) gets ethical green light for human trials for COVID-19 fighter Ifenprodil
The scientific process isn’t exactly what you were taught in grade 4. There’s a lot more to it, owing to some historical—well, let’s call them what they are—atrocities, which have taken place as long as white lab-coats have been all the rage in knowledge-defining circles. This process is expensive in both time and money and…